Saturday 17 October 2026 Export ALDX’s income statement to Excel — free account

Aldeyra Therapeutics, Inc.

In the quarter to June 2026, EPS grew 43.8%, free cash flow grew 46.1% and total debt rose 1.33%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.70 0.04 −5.41%

Follow ALDX

Alert me

Market cap: $44.5M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.52

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	2	—	—	1	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.68%

Capital & Financial Ratios $m

Market Cap 44.48

Revenue —

Net Income (23.05)

Free Cash Flow (22.04)

Net Debt (45.09)

Current Ratio 4.91

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.11

Past 5Y EPS Growth —

This Y EPS Growth 39.29%

Next Y EPS Growth 18.24%

Next Y revenue growth —

Next 5Y EPS Growth 36.26%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 4.42%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	143	101	70	45
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	148	104	72	47

	2023	2024	2025	Q'26
Payables	1	0	0	0
ST’ Debt	15	0	15	—
Other	—	—	—	—
	22	19	28	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	5.93%	(5.75%)	(33.58%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(12)	(9)	(7)	(5)	(33)
’24	(10)	(13)	(8)	(12)	(43)
’23	(9)	(13)	(8)	1	(30)
’22	(13)	(20)	(13)	(11)	(57)
’21	(13)	(9)	(8)	(12)	(43)
’20	(15)	(8)	(6)	(8)	(37)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(5)	(5)	—	—	—
’25	(12)	(9)	(7)	(5)	(33)
’24	(10)	(13)	(8)	(12)	(43)
’23	(9)	(13)	(8)	1	(30)
’22	(13)	(20)	(13)	(11)	(57)
’21	(13)	(9)	(8)	(12)	(43)
’20	(15)	(8)	(6)	(8)	(37)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.06)	(0.09)	—	—	—
’25	(0.17)	(0.16)	(0.13)	(0.11)	(0.56)
’24	(0.14)	(0.28)	(0.25)	(0.27)	(0.94)
’23	(0.27)	(0.15)	(0.14)	(0.08)	(0.64)
’22	(0.29)	(0.30)	(0.25)	(0.22)	(1.06)
’21	(0.25)	(0.28)	(0.27)	(0.27)	(1.07)
’20	(0.34)	(0.25)	(0.23)	(0.35)	(1.11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.39	3.80	6.25	4.31	1.48	3.37	2.36	1.42	2.71	1.14	Analyst estimates 2026–2028 Powerpack
	High	8.19	11.90	16.70	12.79	8.70	15.95	7.99	11.97	6.55	7.20
People
People	Employees	11	12	19	20	11	12	15	10	9	8
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(19)	(22)	(39)	(62)	(38)	(58)	(62)	(38)	(56)	(34)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(19)	(22)	(39)	(61)	(38)	(58)	(62)	(38)	(56)	(34)
	Depreciation	0	0	0	0	1	0	0	0	(1)	(1)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(1.65)	(1.40)	(1.79)	(2.24)	(1.11)	(1.07)	(1.06)	(0.64)	(0.94)	(0.56)
	Cash flow	(1.33)	(1.21)	(1.38)	(1.66)	(1.10)	(0.79)	(0.97)	(0.51)	(0.73)	(0.56)
	Capex	0.00	0.00	(0.01)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(1.34)	(1.21)	(1.39)	(1.66)	(1.10)	(0.79)	(0.97)	(0.51)	(0.73)	(0.56)
	Book value	1.91	2.49	3.99	1.77	1.75	3.81	2.59	2.03	1.19	0.74
	Shares, m	11	16	22	27	34	54	58	59	59	60
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(15)	(19)	(30)	(45)	(37)	(43)	(57)	(30)	(43)	(33)
	Capex	0	0	0	0	—	0	0	—	—	—
	Free cash flow	(15)	(19)	(30)	(45)	(37)	(43)	(57)	(30)	(43)	(33)
Balance, $m
Balance, $m	Working capital	23	41	86	62	71	221	166	126	85	44
	Total debt	1	1	—	15	15	16	16	15	15	15
	Net debt	(24)	(42)	(94)	(59)	(63)	(214)	(158)	(128)	(86)	(55)
	Shareholders’ equity	22	40	87	48	60	206	151	120	71	44
Returns, %
Returns, %	ROA	(70.05)	(64.42)	(55.85)	(71.31)	(47.28)	(36.51)	(29.93)	(22.78)	(44.16)	(38.32)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(80.38)	(72.95)	(61.63)	(90.31)	(69.81)	(43.56)	(34.77)	(27.73)	(58.54)	(58.73)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLNN Clene Inc.	$47.0M	— (loss-making)	— (loss-making)	+233.33% (above 0%: growing)	n/m	+45.43% (above 0%: growing)	60.00%	(5,941.11%)	Compare
TVGN Tevogen Inc.	$46.1M	— (loss-making)	—	—	n/m	+5.78% (above 0%: growing)	—	0.00%	Compare
INMB INmune Bio, Inc.	$45.8M	— (loss-making)	— (loss-making)	+8.70% (above 0%: growing)	n/m	+55.39% (above 0%: growing)	100.00%	0.00%	Compare
IMA ImageneBio, Inc.	$45.7M	— (loss-making)	— (loss-making)	−60.08% (below 0%: shrinking)	n/m	+23.76% (above 0%: growing)	100.00%	0.00%	Compare
SER Serina Therapeutics, Inc.	$45.5M	— (loss-making)	— (loss-making)	+2,500.00% (above 0%: growing)	n/m	−76.82% (below 0%: shrinking)	100.00%	0.00%	Compare
ANVS Annovis Bio, Inc.	$44.8M	— (loss-making)	—	—	n/m	−329.18% (below 0%: shrinking)	—	0.00%	Compare
ALDX Aldeyra Therapeutics, Inc.	$44.5M	— (loss-making)	—	—	n/m	+46.09% (above 0%: growing)	0.00%	0.00%
CELU Celularity, Inc.	$43.2M	— (loss-making)	— (loss-making)	−66.34% (below 0%: shrinking)	n/m	+148.35% (above 0%: growing)	62.25%	(263.47%)	Compare
DWTX Dogwood Therapeutics, Inc	$42.5M	— (loss-making)	—	—	n/m	+10.31% (above 0%: growing)	—	0.00%	Compare
Median of peers	$45.6M	—	—	+8.70%	—	+17.04%	100.00%	0.00%

All 614 Biotechnology stocks →

Aldeyra Therapeutics, Inc. (ALDX) key facts

Concern: Aldeyra Therapeutics, Inc. reported a net loss of $33.8 million, or a loss of $0.56 per share, for fiscal 2025.
Aldeyra Therapeutics, Inc. (ALDX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALDX traded at $0.70, a market capitalization of $44.5 million.
Return on equity was −58.7% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.